Analysis
New drugs: where did we go wrong and what can we do better?
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4340 (Published 10 July 2019) Cite this as: BMJ 2019;366:l4340
Related articles
- Research Published: 04 October 2017; BMJ 359 doi:10.1136/bmj.j4530
- Research Published: 23 September 2015; BMJ 351 doi:10.1136/bmj.h4633
- Analysis Published: 09 November 2016; BMJ 355 doi:10.1136/bmj.i5792
- Analysis Published: 23 October 2015; BMJ 351 doi:10.1136/bmj.h5542
- Research Published: 03 May 2017; BMJ 357 doi:10.1136/bmj.j1680
- PAPERS Published: 02 September 2005; BMJ doi:10.1136/bmj.38582.703866.AE
- Paper Published: 06 October 2005; BMJ 331 doi:10.1136/bmj.38582.703866.AE
- Editorial Published: 25 July 2018; BMJ 362 doi:10.1136/bmj.k3193
- Editorial Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5399
- Research Published: 07 October 2020; BMJ 371 doi:10.1136/bmj.m3434
- Analysis Published: 08 October 2020; BMJ 371 doi:10.1136/bmj.m3841
- Editorial Published: 30 November 2021; BMJ 375 doi:10.1136/bmj.n2883
- Analysis Published: 02 December 2021; BMJ 375 doi:10.1136/bmj.n2374
See more
- When I use a word . . . . The Lelamour HerbalBMJ January 27, 2023, 380 p225; DOI: https://doi.org/10.1136/bmj.p225
- A bill before parliament for the right to breath clean airBMJ January 27, 2023, 380 p224; DOI: https://doi.org/10.1136/bmj.p224
- “Functional disorders”: one of medicine’s biggest failuresBMJ January 27, 2023, 380 p221; DOI: https://doi.org/10.1136/bmj.p221
- Medical academic workforce is under threat without urgent action on pay and pensions, say peersBMJ January 27, 2023, 380 p220; DOI: https://doi.org/10.1136/bmj.p220
- Maternity care: Entonox is withdrawn from some hospitals because of risk to staff from high exposureBMJ January 27, 2023, 380 p212; DOI: https://doi.org/10.1136/bmj.p212
Cited by...
- Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
- Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
- Making medicines safer?
- Flawed evidence underpins approval of new cancer drugs